PHARMACOECONOMICAL ASPECT OF ONCOLOGICAL THERAPY

Author(s)

Viliam Foltán, prof, Head of Department of Organisation and Management in Pharmacy1, Veronika Dubajova, PharmDr, Resarcher1, Dominik Tomek, PharmD, MPH, Researcher2, Milan Dubaj, MD, Researcher31Comenius University, Bratislava, Slovak Republic; 2 Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic; 3 University Hospital, Nitra, Slovak Republic

OBJECTIVES: In current era the costs of the health keeping are increasing, therefore the pharmacoeconomic has determing role. Analysis includes all stages of health keeping , but spotlights are drug costs. Selection of drugs according general criteria helps to save public finance and allows it better utilization. METHODS Valuation of utilization of drugs in oncological practice is based on data from the State Institute for Drug Control in Slovakia which have been evaluated for time period 10 years. Data from the Public Health Insurance, which consist of drug costs, costs on diagnostic and therapy of oncological diseases, are attached to the former data. RESULTS: Public Health Insurance invested €0.19 mld on the therapy of the patients with oncological disease, which presented 10% from all costs on health keeping. Drugs represented about 38% , hospitalization represented 28%, costs of diagnostic represented 15% and ambulation health keeping represented 14%. But costs on ambulation health keeping have increased more than 28%, drug costs more than 15% and diagnostic costs more than 13%. According these data the most expensive diagnosis are breast cancer, colorectal cancer and the cancer of lungs. CONCLUSIONS Health Insurances as financial institutions play the most important role in payment of complex therapy of oncological patients. Because of new technology on diagnostic and therapy in oncology, economic value of costs is increasing. Costs of modern oncological therapy per one patient are more than approximately €1000.

Conference/Value in Health Info

2009-05, ISPOR 2009, Orlando, FL, USA

Value in Health, Vol. 12, No. 3 (May 2009)

Code

PCN44

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×